Home › Research › Biomarkers
Advances in blood biomarkers for Alzheimer disease (AD): A review
Assfaw AD, Schindler SE, Morris JC.. The Kaohsiung journal of medical sciences, 2024-06-18
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer disease (AD) and Alzheimer Disease and Related Dementias (AD/ADRD) are growing public health challenges globally affecting millions of older adults, necessitating concerted efforts to advance our understanding and management of these conditions. AD is a progressive neurodegenerative disorder characterized pathologically by amyloid plaques and tau neurofibrillary tangles that are the primary cause of dementia in older individuals. Early and accurate diagnosis of AD dementia is crucial for effective intervention and treatment but has proven challenging to accomplish. Although testing for AD brain pathology with cerebrospinal fluid (CSF) or positron emission tomography (PET) has been available for over 2 decades, most patients never underwent this testing because of inaccessibility, high out-of-pocket costs, perceived risks, and the lack of AD-specific treatments. However, in recent years, rapid progress has been made in developing blood biomarkers for AD/ADRD. Consequently, blood biomarkers have emerged as promising tools for non-invasive and cost-effective diagnosis, prognosis, and monitoring of AD progression. This review presents the evolving landscape of blood biomarkers in AD/ADRD and explores their potential applications in clinical practice for early detection, prognosis, and therapeutic interventions. It covers recent advances in blood biomarkers, including amyloid beta (Aβ) peptides, tau protein, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). It also discusses their diagnostic and prognostic utility while addressing associated challenges and limitations. Future research directions in this rapidly evolving field are also proposed.
What this study adds
Evidence grade: Low
This is a narrative review. This review describes how blood biomarkers for Alzheimer's disease are being developed as non-invasive and cost-effective tools for diagnosis, prognosis, and monitoring progression. It does not report a new treatment or cure, only the current state of research into these blood tests.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Assfaw, A. D., Schindler, S. E., & Morris, J. C. (2024). Advances in blood biomarkers for Alzheimer disease (AD): A review. The Kaohsiung journal of medical sciences. https://doi.org/10.1002/kjm2.12870
Vancouver
Assfaw AD, Schindler SE, Morris JC. Advances in blood biomarkers for Alzheimer disease (AD): A review. The Kaohsiung journal of medical sciences. 2024. doi:10.1002/kjm2.12870. PMID: 38888066.
BibTeX
@article{assfaw2024-38888066,
author = {Assfaw, A. D. and Schindler, S. E. and Morris, J. C.},
title = {{Advances in blood biomarkers for Alzheimer disease (AD): A review}},
journal = {The Kaohsiung journal of medical sciences},
year = {2024},
doi = {10.1002/kjm2.12870},
pmid = {38888066},
url = {https://doi.org/10.1002/kjm2.12870}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Consequently, blood biomarkers have emerged as promising tools for non-invasive and cost-effective diagnosis, prognosis, and monitoring of AD progression.
- This review presents the evolving landscape of blood biomarkers in AD/ADRD and explores their potential applications in clinical practice for early detection, prognosis, and therapeutic interventions.
- It covers recent advances in blood biomarkers, including amyloid beta (Aβ) peptides, tau protein, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP).
- It also discusses their diagnostic and prognostic utility while addressing associated challenges and limitations.
- Future research directions in this rapidly evolving field are also proposed.
Why it matters
This review describes how blood biomarkers for Alzheimer's disease are being developed as non-invasive and cost-effective tools for diagnosis, prognosis, and monitoring progression. It does not report a new treatment or cure, only the current state of research into these blood tests.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Kaohsiung journal of medical sciences) |
| Journal's citation record | 0 / 4 | The Kaohsiung Journal of Medical Sciences: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 41 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.2 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 4 / 6 | Cited 11.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 41 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author John C. Morris: h-index 209 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38888066) |
| Free to read | 2 / 2 | Free to read |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 21.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Biomarkers from nearby years
Also in Biomarkers
141 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.